

Press Release – For immediate release

BIOLIDICS ENTERS INTO A STRATEGIC COLLABORATION WITH SYSMEX CORPORATION

- Biolidics and Sysmex to jointly collaborate and develop laboratory assays in the field of circulating tumor cells
- A global leader in the hematology, hemostasis and urinalysis fields, Sysmex delivers total solutions in the domain of healthcare testing, supplying products and services to customers in more than 190 countries
- Key objective of the strategic collaboration is to promote laboratory assays developments, applications and market developments for the potential commercialisation of these laboratory assays

Singapore, 20 February 2019 – Biolidics Limited ("Biolidics" or the "Company"), a medical technology company with a focus on cancer diagnostic solutions, is pleased to announce that it has today entered into a non-binding term sheet with one of the leading suppliers of hematology instruments, Japan-based Sysmex Corporation ("Sysmex"), for strategic collaboration on the development of laboratory assays in the field of circulating tumour cells utilising the Company's ClearCell® FX1 System and Sysmex's molecular imaging flow cytometer MI-FCM in Japan and Singapore respectively.

In addition, Biolidics and Sysmex will promote laboratory assay developments, applications and market developments for the potential commercialisation of these laboratory assays.

Listed on the Tokyo Stock Exchange with a market capital of approximately S\$17 billion as at 18 February 2019, Sysmex delivers total solutions in the domain of healthcare testing, supplying products and services to customers in more than 190 countries. Globally, Sysmex has the number 1 market share in the hematology, hemostasis and urinalysis fields. In 2018, Sysmex registered net sales of ¥281.9 billion with an operating profit of ¥59.0 billion.

Biolidics' ClearCell® FX1 System has the potential, when coupled with other analytical tests, to serve as a platform technology for the diagnosis, prognosis, treatment selection and treatment monitoring of various types of cancers, through the development of a wide range of clinical or laboratory assays.

Hence, one of Biolidics' key business focus is to develop end-to-end diagnostic solutions which integrate its cell separation and enrichment technology with other analytical tests, thereby further enhancing the commercial scalability of its technology and allowing the ClearCell® FX1 System to be used in a greater number of hospitals and laboratories globally.

Mr. Ivan Lew, Executive Director and CEO of Biolidics, said: "With a 50-year track record, Sysmex is one of the globally recognized leaders in the area of healthcare testing in blood-based diagnostic tests. By forging this strategic collaboration, Biolidics will be ideally



positioned to increase the sales potential of our ClearCell® FX1 System and CTChip® FR1 biochip once these blood-based assays are approved clinically."

- END -

About Biolidics Limited

Incorporated in 2009, Biolidics is a Singapore-based medical technology company focusing on the development of cell enrichment systems which, when combined with other analytical tests, have a wide range of applications for cancer diagnosis, prognosis, treatment selection and treatment monitoring.

Biolidics has developed and commercialised the ClearCell® FX1 System, a fully automated IVD medical device which relies on a novel patented technology to separate and enrich cancer cells from blood.

With ClearCell® FX1 Systems installed across Asia, Europe and North America, the ClearCell® FX1 System allows users of the system to perform liquid biopsies to test for the presence of cancer cells (specifically circulating tumour cells, or CTCs) in blood samples or perform further analysis on cancer cells.

Liquid biopsies (i.e. analysis of the circulating tumour cells in blood samples) have many applications throughout the various stages of a patient's cancer journey, from cancer screening and staging to personalised treatment, and post-cancer monitoring.

Biolidics' quality assurance capabilities have been recognised through its ISO 13485 certification, CE-IVD, US FDA Class I registration and CFDA Class I registration (for the MGI EasyCell System).

For additional information, please visit <u>www.biolidics.com.</u>

Issued on behalf of Biolidics Limited by 8PR Asia Pte Ltd.

Media & Investor Contacts:

8PR asia

Mr. Alex TAN

Mobile: +65 9451 5252

Email: alex.tan@8prasia.com

This press release has been prepared by the Company and its contents have been reviewed by the Company's sponsor, United Overseas Bank Limited (the "Sponsor"), for compliance with the relevant rules of the Singapore Exchange Securities Trading Limited (the "SGX-ST").

The Sponsor has not independently verified the contents of this press release. This press release has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this press release, including the correctness of any of the statements or opinions made or reports contained in this press release.

The contact person for the Sponsor is Mr Chia Beng Kwan, Senior Director, Equity Capital Markets, who can be contacted at 80 Raffles Place, #03-03 UOB Plaza 1, Singapore 048624, telephone: +65 6533 9898.